Author

Patricia Carrera-Lasfuentes

EVIDENCE-BASED SELECTION ON THE APPROPRIATE FIT CUT-OFF POINT IN CRC SCREENING PROGRAMS IN THE COVID PANDEMIC
EVIDENCE-BASED SELECTION ON THE APPROPRIATE FIT CUT-OFF POINT IN CRC SCREENING PROGRAMS IN THE COVID PANDEMIC

EVIDENCE-BASED SELECTION ON THE APPROPRIATE FIT CUT-OFF POINT IN CRC SCREENING PROGRAMS IN THE COVID PANDEMIC
EVIDENCE-BASED SELECTION ON THE APPROPRIATE FIT CUT-OFF POINT IN CRC SCREENING PROGRAMS IN THE COVID PANDEMIC

Patricia Carrera-Lasfuentes  et al.

MANAGEMENT OF HELICOBACTER PYLORI INFECTION DURING THE LAST DECADE: TEMPORAL PRESCRIPTION TRENDS FOR THE FIRST-LINE OF NON-ALLERGIC PATIENTS AND ITS ADEQUACY TO CLINICAL GUIDELINES
MANAGEMENT OF HELICOBACTER PYLORI INFECTION DURING THE LAST DECADE: TEMPORAL PRESCRIPTION TRENDS FOR THE FIRST-LINE OF NON-ALLERGIC PATIENTS AND ITS ADEQUACY TO CLINICAL GUIDELINES

Patricia Carrera-Lasfuentes  et al.

FIRST-LINE HELICOBACTER PYLORI ERADICATION RATE IN DAILY CLINICAL PRACTICE IN TWO SPANISH MEDICAL CENTERS: 2010-2019
FIRST-LINE HELICOBACTER PYLORI ERADICATION RATE IN DAILY CLINICAL PRACTICE IN TWO SPANISH MEDICAL CENTERS: 2010-2019

Patricia Carrera-Lasfuentes  et al.

CHARACTERISTICS OF PATIENTS WITH HELICOBACTER PYLORI INFECTION WHO STOP CLINICAL SURVEILLANCE IN GASTROENTEROLOGY CLINICS
CHARACTERISTICS OF PATIENTS WITH HELICOBACTER PYLORI INFECTION WHO STOP CLINICAL SURVEILLANCE IN GASTROENTEROLOGY CLINICS

Patricia Carrera-Lasfuentes  et al.

MISTAKES IN DIAGNOSTIC AND THERAPEUTIC MANAGEMENT OF HELICOBACTER PYLORI INFECTION IN THE LAST DECADE
MISTAKES IN DIAGNOSTIC AND THERAPEUTIC MANAGEMENT OF HELICOBACTER PYLORI INFECTION IN THE LAST DECADE

Patricia Carrera-Lasfuentes  et al.

ERRORS IN EMPIRICAL ANTIBIOTIC THERAPIES FOR HELICOBACTER PYLORI ERADICATION IN 45,778 PATIENTS: DATA FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
ERRORS IN EMPIRICAL ANTIBIOTIC THERAPIES FOR HELICOBACTER PYLORI ERADICATION IN 45,778 PATIENTS: DATA FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Patricia Carrera-Lasfuentes  et al.

COLORECTAL CANCER PROGNOSIS AND DIAGNOSIS UTILITY OF A NEW NON INVASIVE INFLAMMATORY BLOOD BIOMARKER
COLORECTAL CANCER PROGNOSIS AND DIAGNOSIS UTILITY OF A NEW NON INVASIVE INFLAMMATORY BLOOD BIOMARKER

Patricia Carrera-Lasfuentes  et al.

FALSE POSITIVES IN FECAL IMMUNOCHEMICAL TEST IN COLORECTAL CANCER SCREENING AND THE RELATION WITH HARMFUL GASTROINTESTINAL DRUGS: THE IMPORTANCE OF THE EFFECT OF COMBINING PPI AND GASTROINTESTINAL DAMAGING DRUGS
FALSE POSITIVES IN FECAL IMMUNOCHEMICAL TEST IN COLORECTAL CANCER SCREENING AND THE RELATION WITH HARMFUL GASTROINTESTINAL DRUGS: THE IMPORTANCE OF THE EFFECT OF COMBINING PPI AND GASTROINTESTINAL DAMAGING DRUGS

Patricia Carrera-Lasfuentes  et al.

ASSESSMENT OF THE FECAL IMMUNOCHEMICAL TEST CUTOFF LEVEL IN SCREENING POPULATION DEPENDING ON GENDER
ASSESSMENT OF THE FECAL IMMUNOCHEMICAL TEST CUTOFF LEVEL IN SCREENING POPULATION DEPENDING ON GENDER

Patricia Carrera-Lasfuentes  et al.

IMPACT OF THE COVID-19 PANDEMIC IN THE DIAGNOSIS AND CHARACTERISTICS OF COLORECTAL CANCER PATIENTS
IMPACT OF THE COVID-19 PANDEMIC IN THE DIAGNOSIS AND CHARACTERISTICS OF COLORECTAL CANCER PATIENTS

Patricia Carrera-Lasfuentes  et al.

Item 1 - 11 / 11
1